



Revision date: 03-Nov-2016 Version: 1.0 Page 1 of 10

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Epinephrine Injection (Hospira, Inc.)

Trade Name: Not applicable Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for allergic reactions (anaphylaxis)

**Details of the Supplier of the Safety Data Sheet** 

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited

Horizon Honey Lane Hurley

Maidenhead, SL6 6RJ United Kingdom

**Emergency telephone number:** 

International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number: CHEMTREC (24 hours): 1-800-424

CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

# 2. HAZARDS IDENTIFICATION

**Classification of the Substance or Mixture** 

GHS - Classification Not classified as hazardous

**Label Elements** 

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

**Note:** This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Material Name: Epinephrine Injection (Hospira, Inc.)

Revision date: 03-Nov-2016

Page 2 of 10

Version: 1.0

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Epinephrine	51-43-4	200-098-7	Acute Tox. 2 (H300) Acute Tox. 2 (H310)	1.0
Sodium bisulfite	7631-90-5	231-548-0	Acute Tox. 4 (H302)	<2.0
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
Sodium chloride	7647-14-5	231-598-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS	GHS Classification	%
		List		
Water for Injection	7732-18-5	231-791-2	Not Listed	*
Sodium citrate	68-04-2	200-675-3	Not Listed	*

Additional Information: \* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

For the full text of the R phrases mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

**Description of First Aid Measures** 

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion** 

**Products:** 

Formation of toxic gases is possible during heating or fire.

Material Name: Epinephrine Injection (Hospira, Inc.)

Revision date: 03-Nov-2016 Version: 1.0

Fine / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

### **Advice for Fire-Fighters**

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spilled material by a method that

Collecting: controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Additional Consideration for** 

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Page 3 of 10

### 7. HANDLING AND STORAGE

#### **Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Sodium bisulfite

**ACGIH Threshold Limit Value (TWA)** 5 mg/m<sup>3</sup> **Australia TWA** 5 mg/m<sup>3</sup> **Belgium OEL - TWA** 5 mg/m<sup>3</sup> **Denmark OEL - TWA** 5 mg/m<sup>3</sup>  $5 \text{ mg/m}^3$ France OEL - TWA **Greece OEL - TWA** 5 mg/m<sup>3</sup> **Ireland OEL - TWAs**  $5 \text{ mg/m}^3$ Portugal OEL - TWA  $5 \text{ mg/m}^3$ Spain OEL - TWA 5 mg/m<sup>3</sup> **Switzerland OEL -TWAs** 5 mg/m<sup>3</sup> Vietnam OEL - TWAs 5 mg/m<sup>3</sup>

### HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: 2 ppm

Material Name: Epinephrine Injection (Hospira, Inc.)

Page 4 of 10

Revision date: 03-Nov-2016 Version: 1.0

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8. EX	XPOSURE CONTROLS / PERSONAL PROTECT	ION			
	Australia PEAK	5 ppm 7.5 mg/m <sup>3</sup>			
	Austria OEL - MAKs	5 ppm 8 mg/m <sup>3</sup>			
	Belgium OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Bulgaria OEL - TWA	5 ppm 8.0 mg/m <sup>3</sup>			
	Cyprus OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Czech Republic OEL - TWA	8 mg/m <sup>3</sup>			
	Estonia OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Germany - TRGS 900 - TWAs	2 ppm 3 mg/m <sup>3</sup>			
	Germany (DFG) - MAK	2 ppm 3.0 mg/m <sup>3</sup>			
	Greece OEL - TWA	5 ppm 7 mg/m <sup>3</sup>			
	Hungary OEL - TWA	8 mg/m <sup>3</sup>			
	Ireland OEL - TWAs	5 ppm			
		8 mg/m <sup>3</sup>			
	Italy OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Japan - OELs - Ceilings	2 ppm 3.0 mg/m <sup>3</sup>			
	Latvia OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Lithuania OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Luxembourg OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Malta OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Netherlands OEL - TWA	8 mg/m <sup>3</sup>			
	Poland OEL - TWA	5 mg/m <sup>3</sup>			
	Portugal OEL - TWA	5 ppm			
		8 mg/m <sup>3</sup>			
	Romania OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Slovakia OEL - TWA	5 ppm 8.0 mg/m <sup>3</sup>			
	Slovenia OEL - TWA	5 ppm 8 mg/m <sup>3</sup>			
	Spain OEL - TWA	5 ppm 7.6 mg/m <sup>3</sup>			
	Switzerland OEL -TWAs	2 ppm 3.0 mg/m <sup>3</sup>			
	Vietnam OEL - TWAs	5 mg/m <sup>3</sup>			
Sodium chloride					
	Latvia OEL - TWA	5 mg/m <sup>3</sup>			
	Lithuania OEL - TWA	5 mg/m <sup>3</sup>			
		<del>-</del>			

D70000

Material Name: Epinephrine Injection (Hospira, Inc.) Page 5 of 10 Revision date: 03-Nov-2016 Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Epinephrine** 

Band (OEB):

Pfizer Occupational Exposure OEB 4 - Skin (control exposure to the range of 1ug/m³ to <10ug/m³, provide additional

precautions to protect from skin contact)

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

**Personal Protective** 

**Equipment:** 

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and

specific operational processes.

Hands: Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug

product is possible and for bulk processing operations. (Protective gloves must meet the

standards in accordance with EN374, ASTM F1001 or international equivalent.)

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the Eyes:

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Wear impervious protective clothing to prevent skin contact - consider use of disposable Skin:

clothing where appropriate. (Protective clothing must meet the standards in accordance with

EN13982, ANSI 103 or international equivalent.)

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is Respiratory protection:

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Liquid **Physical State:** 

No data available. Odor:

Molecular Formula: Mixture Color: Clear colorless No data available. **Odor Threshold:** 

**Molecular Weight:** Mixture

**Solvent Solubility:** No data available Water Solubility: No data available Soluble: Water Solubility: pH: 2.2-5.0

No data available **Melting/Freezing Point (°C): Boiling Point (°C):** No data available. Partition Coefficient: (Method, pH, Endpoint, Value)

**Epinephrine** No data available Sodium bisulfite No data available

Water for Injection No data available Sodium chloride

No data available Sodium citrate No data available

HYDROCHLORIC ACID

No data available

**Decomposition Temperature (°C):** No data available.

Page 6 of 10

Material Name: Epinephrine Injection (Hospira, Inc.)

Revision date: 03-Nov-2016 Version: 1.0

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available
No data available
No data available

Specific Gravity: ~1

Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

### 10. STABILITY AND REACTIVITY

Reactivity: No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

Oxidizing Properties: No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

**Products:** 

### 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual

ingredients.

**Short Term:** May be absorbed through the skin and cause systemic effects. May be absorbed through

mucous membranes and cause systemic effects.

Known Clinical Effects: Adverse effects associated with therapeutic use include increased heart rate (tachycardia).

palpitations, sweating, nausea, vomiting, difficulty breathing, dizziness, weakness, headache,

anxiety, nervousness.

Acute Toxicity: (Species, Route, End Point, Dose)

**Epinephrine** 

Rat Dermal LD50 62 mg/kg Rat Oral LD50 30mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Material Name: Epinephrine Injection (Hospira, Inc.)

Revision date: 03-Nov-2016

Version: 1.0

TOTALION GALLO. GO NOV 2010

## 11. TOXICOLOGICAL INFORMATION

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Epinephrine** 

Embryo / Fetal Development Rat Intravenous Dose not specified Not teratogenic

Embryo / Fetal Development Rabbit Subcutaneous 30 times human dose LOAEL Developmental toxicity Embryo / Fetal Development Mouse Subcutaneous 7 times human dose LOAEL Developmental toxicity

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**Epinephrine** 

Bacterial Mutagenicity (Ames) Salmonella Negative Sister Chromatid Exchange Negative with activation

Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Equivocal without activation

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vivo Micronucleus Rat Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Sodium bisulfite

IARC: Group 3 (Not Classifiable)

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

# 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

\_\_\_\_\_

Material Name: Epinephrine Injection (Hospira, Inc.)

Revision date: 03-Nov-2016

Version: 1.0

10/0/0/11

### 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Additional Information: The US Federal EPA waste listing for epinephrine does not include epinephrine salts. Disposal

should be performed in accordance with all federal, state, and local regulatory requirements.

**Epinephrine** 

RCRA - P Series Wastes Listed

# 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### **Epinephrine**

Not Listed CERCLA/SARA 313 Emission reporting **CERCLA/SARA Hazardous Substances** 1000 lb and their Reportable Quantities: 454 kg Not Listed **California Proposition 65** Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 3 for Drugs and Poisons: Schedule 4 **EU EINECS/ELINCS List** 200-098-7

Sodium bisulfite

CERCLA/SARA 313 Emission reporting

CERCLA/SARA Hazardous Substances

and their Reportable Quantities:

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

5000 lb

2270 kg

Not Listed

Present

2270 kg

Not Listed

Present

231-548-0

Material Name: Epinephrine Injection (Hospira, Inc.) Page 9 of 10 Revision date: 03-Nov-2016 Version: 1.0

### 15. REGULATORY INFORMATION

#### Water for Injection

**CERCLA/SARA 313 Emission reporting** Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **REACH - Annex IV - Exemptions from the** Present

obligations of Register:

**EU EINECS/ELINCS List** 231-791-2

#### HYDROCHLORIC ACID

**CERCLA/SARA 313 Emission reporting** 1.0 % **CERCLA/SARA Hazardous Substances** 5000 lb and their Reportable Quantities: 2270 kg **CERCLA/SARA - Section 302 Extremely Hazardous** 500 lb

**TPQs** 

**CERCLA/SARA - Section 302 Extremely Hazardous** 5000 lb

**Substances EPCRA RQs** 

**California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5 for Drugs and Poisons: Schedule 6 **EU EINECS/ELINCS List** 231-595-7

### Sodium chloride

**CERCLA/SARA 313 Emission reporting** Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 231-598-3

### Sodium citrate

**CERCLA/SARA 313 Emission reporting** Not Listed Not Listed **California Proposition 65** Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 200-675-3

## 16. OTHER INFORMATION

## Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed

Acute toxicity, dermal-Cat.2; H310 - Fatal in contact with skin

Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage

Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

**Data Sources:** Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision: New data sheet.

Material Name: Epinephrine Injection (Hospira, Inc.)

Revision date: 03-Nov-2016

Page 10 of 10

Version: 1.0

Revision date: 03-Nov-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet** 

\_\_\_\_\_